首页> 外文OA文献 >MicroRNA EXPRESSION PROFILE HELPS TO DISTINGUISH BENIGN NODULES FROM PAPILLARY THYROID CARCINOMAS STARTING FROM CELLS OF FINE NEEDLE ASPIRATION.
【2h】

MicroRNA EXPRESSION PROFILE HELPS TO DISTINGUISH BENIGN NODULES FROM PAPILLARY THYROID CARCINOMAS STARTING FROM CELLS OF FINE NEEDLE ASPIRATION.

机译:MicroRNA表达谱有助于区分细小针状甲状腺癌从细针吸出细胞开始的乳头状甲状腺癌的良性结节。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVE:\ud\udMicroRNAs (miRNAs) are small endogenous non-coding RNAs that pair with target messengers regulating gene expression. Changes in miRNA levels occur in thyroid cancer. Fine needle aspiration (FNA) with cytologic evaluation is the most reliable tool for malignancy prediction in thyroid nodules, but cytologic diagnosis remains undetermined for 20% of nodules.\ud\udDESIGN:\ud\udIn this study we evaluated the expression of 7 miRNAs in benign nodules, papillary thyroid carcinomas (PTC) and undetermined nodules at FNA.\ud\udMETHODS:\ud\udThe prospective study included 141 samples obtained by FNA of thyroid nodules from 138 patients. miRNA expression was evaluated by quantitative RT-PCR and statistical analysis of data was performed. Genetic analysis of codon 600 of BRAF gene was also performed.\ud\udRESULTS:\ud\udUsing data mining techniques we obtained a criterion to classify a nodule as benign or malignant on the basis of miRNA expression. The decision model based on the expression of miR-146b, miR-155 and miR-221 was valid for 86/88 nodules with determined cytology (97.73%), and adopting cross-validation techniques we obtained a reliability of 78.41%. The prediction was valid for 31/53 undetermined nodules with 16 false positive and 6 false negative predictions. The mutated form V600E of BRAF gene was demonstrated in 19/43 PTCs and in 1/53 undetermined nodules.\ud\udCONCLUSIONS:\ud\udThe expression profiles of three miRNAs allowed to distinguish benign from PTC starting from FNA. When the assay was applied to discriminate thyroid nodules with undetermined cytology a low sensitivity and specificity despite the low number of false negative predictions was obtained, limiting the practical interest of the method.
机译:目的:\ ud \ udMicroRNA(miRNA)是小的内源非编码RNA,与调节基因表达的靶信使配对。 miRNA水平的变化发生在甲状腺癌中。细针穿刺术(FNA)和细胞学评估是预测甲状腺结节恶性肿瘤最可靠的工具,但对于20%的结节,细胞学诊断仍未确定。\ ud \ udDESIGN:\ ud \ ud在良性结节,乳头状甲状腺癌(PTC)和未确定的结节处的FNA。\ ud \ ud方法:\ ud \ ud前瞻性研究包括FNA从138例甲状腺结节中获得的141个样本。通过定量RT-PCR评估miRNA表达,并进行数据统计分析。还对BRAF基因的600号密码子进行了遗传分析。\ ud \ ud结果:\ ud \ ud使用数据挖掘技术,我们根据miRNA的表达获得了将结节分类为良性还是恶性的标准。基于miR-146b,miR-155和miR-221的表达的决策模型对于细胞学确定的86/88结节有效(97.73%),采用交叉验证技术,我们获得了78.41%的可靠性。该预测对31/53个未定结节有效,其中有16个假阳性预测和6个假阴性预测。在19/43个PTC和1/53个未确定的结节中证实了BRAF基因的突变形式V600E。\ ud \ ud结论:\ ud \ ud从FNA开始,三个miRNA的表达谱可区分良性与PTC。当该测定法用于区分细胞学未定的甲状腺结节时,尽管假阴性预测的数量很少,但灵敏度和特异性却很低,从而限制了该方法的实际应用价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号